Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 September 2021, including: Roche Holding AG shores up oncology; Janssen Pharmaceutical Cos.’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID-19.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Roche Gives The Stage To A New Generation Of Cancer Drugs" - Scrip, 15 Sep, 2021.)
(Also see "Working Toward A Cure: Janssen’s Multiple Myeloma Strategy" - Scrip, 13 Sep, 2021.)
(Also see "Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study" - Scrip, 15 Sep, 2021.)
(Also see "Novartis's Tislelizumab Takes First Step On US Approval Path" - Scrip, 13 Sep, 2021.)
(Also see "With Delta Variant Spread, Herd Immunity A ‘Myth’, Says Public Health Expert" - Scrip, 14 Sep, 2021.)